N6-methyladenosine in DNA promotes genome stability
eLife · 2025
DOI: 10.7554/elife.101626 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2025. Verfasst von Brooke A Conti und 15 weiteren Autor:innen. Beteiligte Einrichtung: Centers for Therapeutic Innovation, Emerging Sciences and Innovation, Pfizer, New York, United States. Hauptthemen laut MEDLINE: Adenosine, Genomic Instability, DNA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer's Centers for Therapeutic Innovation.
Abstract (Originalsprache)
DNA base lesions, such as incorporation of uracil into DNA or base mismatches, can be mutagenic and toxic to replicating cells. To discover factors in repair of genomic uracil, we performed a CRISPR knockout screen in the presence of floxuridine, a chemotherapeutic agent that incorporates uracil and fluorouracil into DNA. We identified known factors, such as uracil DNA N-glycosylase (UNG), and unknown factors, such as the N6-adenosine methyltransferase, METTL3, as required to overcome floxuridine-driven cytotoxicity. Visualized with immunofluorescence, the product of METTL3 activity, N6-methyladenosine, formed nuclear foci in cells treated with floxuridine. The observed N6-methyladenosine was embedded in DNA, called 6mA, and these results were confirmed using an orthogonal approach, liquid chromatography coupled to tandem mass spectrometry. METTL3 and 6mA were required for repair of lesions driven by additional base-damaging agents, including raltitrexed, gemcitabine, and hydroxyurea. Our results establish a role for METTL3 and 6mA in promoting genome stability in mammalian cells, especially in response to base damage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centers for Therapeutic Innovation, Emerging Sciences and Innovation, Pfizer, New York, United States.
- Target Sciences, Emerging Sciences and Innovation, Pfizer, New York, United States.
- Discovery Sciences, Pfizer, Groton, United States.
- Laboratory of Nuclear Organization, Cecil H. and Ida Green Center for Reproductive Biology Sciences, Division of Basic Research, Department of Obstetrics and Gynecology, Department of Molecular Biology, Hamon Center for…
- Target Sciences, Emerging Sciences and Innovation, Pfizer, Cambridge, United States.
ORCID-Profile: Brooke A Conti, Mariano Oppikofer
Förderung
- Pfizer's Centers for Therapeutic Innovation
Zitieren
APA
Conti, B. A., Novikov, L., Tong, D., Xiang, Q., Vigil, S., McLellan, T. J., Nguyen, C., De La Cruz, N., Veettil, R. T., Pradhan, P., Sahasrabudhe, P., Arroyo, J. D., Shang, L., Sabari, B. R., Shields, D. J., & Oppikofer, M. (2025). N6-methyladenosine in DNA promotes genome stability. eLife. https://doi.org/10.7554/elife.101626
Vancouver
Conti BA, Novikov L, Tong D, Xiang Q, Vigil S, McLellan TJ, et al. N6-methyladenosine in DNA promotes genome stability. eLife. 2025. doi:10.7554/elife.101626
BibTeX
@article{Conti2025,
author = {Conti, Brooke A and Novikov, Leo and Tong, Deyan and Xiang, Qing and Vigil, Savon and McLellan, Thomas J and Nguyen, Chuong and De La Cruz, Nancy and Veettil, Reshma T and Pradhan, Prashant and Sahasrabudhe, Parag and Arroyo, Jason D and Shang, Lei and Sabari, Benjamin R and Shields, David J and Oppikofer, Mariano},
title = {N6-methyladenosine in DNA promotes genome stability},
journal = {eLife},
year = {2025},
doi = {10.7554/elife.101626}
}
EUVIMED